Pelthos Therapeutics to Participate in Upcoming September Investor Conferences
DURHAM, N.C., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company (“Pelthos” or the “Company”) committed to commercializing innovative therapeutic products for high unmet patient needs, today announced that Scott Plesha, CEO, and Frank Knuettel II, CFO, will participate in the upcoming September conferences: H.C. Wainwright 27th Annual Global Investment Conference and the Investor Summit Group Q3 Virtual Conference.
Investor Conference Details:
H.C. Wainwright 27th Annual Global Investment Conference
Location: Lotte New York Palace Hotel, New York City
Conference Dates: September 8-10, 2025
Presentation Date: September 10, 2025 at 10:30 A.M. ET
One on one meeting availability: September 10, 2025
Institutional investors interested in scheduling an in-person one-on-one meeting should contact their institutional sales rep or register for the conference via this LINK.
A webcast of the presentation will be available on the Events and Presentations pages of Pelthos’ website at https://pelthos.com. Archived replays will be available for 90 days following the event.
Investor Summit Group Q3 Virtual Conference
Location: Virtual
Conference Dates: September 16-17, 2025
To register for this event please visit this LINK.
About Pelthos Therapeutics
Pelthos Therapeutics is a biopharmaceutical company committed to commercializing innovative, safe, and efficacious therapeutic products to help patients with unmet treatment burdens. The company’s lead product ZELSUVMI™ (berdazimer) topical gel, 10.3%, for the treatment of molluscum contagiosum, was approved by the U.S. Food and Drug Administration in 2024. More information is available at www.pelthos.com. Follow Pelthos on LinkedIn and X.
Contacts
Pelthos Investor Inquiries:
Mike Moyer
Managing Director, LifeSci Advisors, LLC
mmoyer@lifesciadvisors.com
Media:
KWM Communications
Kellie Walsh / Rachel Kessler
pelthos@kwmcommunications.com
(914) 315-6072
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
